CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present at the following upcoming conferences:
- Piper Jaffray 26th Annual Health Care Conference, Tuesday, December 2, 2014 at 11:50 a.m. EST in New York, NY
- Oppenheimer 25th Annual Healthcare Conference, Wednesday, December 10, 2014 at 8:35 a.m. EST in New York, NY
Live webcasts of each presentation can be accessed by visiting the investor relations section of the Genocea website at http://ir.genocea.com. Replays of each webcast will be archived for 30 days following the live events.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.